EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Pilot Study of Dynamic Circulating Tumor Cell Profiling for Patients with Hepatocellular Carcinoma Receiving Systemic Therapy

Marcos Santiago Figueroa, Chetan Nambiar, Lauren Jung, Sarah Martin, Samantha Orozco, Anna A. Amankwah, Nada A. Attia, Mingyang Li, Namrata Anand, Sulin Wu, Aurelie Desgardin, Anjana Pillai und 2 weitere

Current Issues in Molecular Biology · 13.11.2026 · 48 (11) · 1214

DOI: 10.3390/cimb48111214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 13.11.2026. Verfasst von Marcos Santiago Figueroa und 13 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research Foundation, GI Research Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) is a leading cause of cancer morbidity and mortality, and patients are often diagnosed with advanced disease or metastasis at time of diagnosis. Characterizing circulating tumor cell (CTC) behavior may shed light on the disease’s natural history and treatment response.

Methods

We used a commercially available, size-based microfluidic purification technology to isolate CTCs from the whole blood of an exploratory prospective cohort of 23 patients receiving systemic therapy for HCC, both prior to treatment and after 6–8 weeks of treatment. CTC concentrations were quantified using on-chip staining with a cocktail of HCC-specific antibodies followed by rare cell image analysis. CTC counts were correlated with standard laboratory and clinical parameters.

Results

Our assay’s sensitivity was higher than previously published. CTC counts did not correlate with disease stage or on-treatment survival. Pre-treatment CTC counts were inversely related to serum alpha-fetoprotein (AFP) levels and were not correlated with circulating tumor DNA quantitative metrics or genomic subsets. On-treatment increase in CTC counts showed a non-significant trend toward improved survival.

Conclusions

Serial CTC enumeration on therapy may serve as a novel liquid biopsy approach that complements the data yielded by conventional biomarkers like AFP and ctDNA. Future work will better define how deeper characterization of CTC dynamics and expression profiling can contribute to biomarker development.

Förderung

  • Cancer Research Foundation
  • GI Research Foundation

Zitieren

APA

Figueroa, M. S., Nambiar, C., Jung, L., Martin, S., Orozco, S., Amankwah, A. A., Attia, N. A., Li, M., Anand, N., Wu, S., Desgardin, A., Pillai, A., Liao, C., & Franses, J. W. (2026). A Pilot Study of Dynamic Circulating Tumor Cell Profiling for Patients with Hepatocellular Carcinoma Receiving Systemic Therapy. Current Issues in Molecular Biology, 48(11), 1214. https://doi.org/10.3390/cimb48111214

Vancouver

Figueroa MS, Nambiar C, Jung L, Martin S, Orozco S, Amankwah AA, et al. A Pilot Study of Dynamic Circulating Tumor Cell Profiling for Patients with Hepatocellular Carcinoma Receiving Systemic Therapy. Current Issues in Molecular Biology. 2026;48(11):1214. doi:10.3390/cimb48111214

BibTeX
@article{Figueroa2026,
  author = {Figueroa, Marcos Santiago and Nambiar, Chetan and Jung, Lauren and Martin, Sarah and Orozco, Samantha and Amankwah, Anna A. and Attia, Nada A. and Li, Mingyang and Anand, Namrata and Wu, Sulin and Desgardin, Aurelie and Pillai, Anjana and Liao, Chih-Yi and Franses, Joseph W.},
  title = {A Pilot Study of Dynamic Circulating Tumor Cell Profiling for Patients with Hepatocellular Carcinoma Receiving Systemic Therapy},
  journal = {Current Issues in Molecular Biology},
  year = {2026},
  volume = {48},
  number = {11},
  pages = {1214},
  doi = {10.3390/cimb48111214}
}
Kostenlos starten →